• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on September 7, 2021October 13, 2023

Soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses: standardized template

Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recomb...
Read More
Posted on August 18, 2020October 13, 2023

Inactivated Viral Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment

Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Bene...
Read More
Posted on June 11, 2020October 13, 2023

Protein Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment

Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccine...
Read More
Posted on June 11, 2020October 13, 2023

Nucleic Acid (RNA And DNA) Vaccines: Standardized Template For Collection Of Key Information For Benefit-Risk Assessment

Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaborati...
Read More
Posted on April 11, 2019October 13, 2023

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment Author links open overlay panel

This tool was aimed at identifying potential major hurdles or gaps that would need to be addressed during the development of vecto...
Read More
Posted on December 12, 2016October 13, 2023

Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment

In this paper, we use a standardized template describing key characteristics of the novel rVSV vaccine vectors, in comparison to...
Read More
Posted on January 1, 2016October 13, 2023

Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment

In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in compa...
Read More
Previous page 1 2

Recent Posts

  • Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine CongressMay 27, 2025
  • Brighton Collaboration News — May 2025May 19, 2025
  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024
  • Lessons Learned from Vaccine Safety Surveillance EffortsSeptember 3, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy